keine Finanzberatung

BIIB · Biogen

Neuroscience-focused biotech — an eroding MS franchise and an Alzheimer's bet

Risiko 6/10 · ELEVATED RISK · pharma in transition · $220.83 ▼ 1.64%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $220.83
  • Market cap $32.6B
  • P/E (ttm) 39.22
  • Div yield none
  • 52-wk range $135.39 – $225.80
  • Index rank #307 / —

Wichtigste Risiken

  • MS franchise erosion outruns new product launches (Shareholders) — HIGH
  • Leqembi ramp stays slower than the market needs (Shareholders) — HIGH
  • Acquired pipeline (RayThera and others) fails in the clinic (Shareholders) — MED
  • US drug-pricing pressure on the whole portfolio (Shareholders) — MED

Fazit

Only for investors who believe the pipeline outruns the erosion; the cheap forward multiple is the market's doubt, not a gift.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.